VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
VolitionRx (NYSE: VNRX), a multi-national epigenetics company, reported its Q1 2025 financial results and business updates. The company recorded $0.25 million in revenue, up 44% year-over-year, while reducing monthly net cash burn to $1.4 million, a 50% reduction from Q1 2024.
Key highlights include ongoing confidential discussions with over ten companies for Nu.Q® platform commercialization in human diagnostics, with seven potential partners having a combined market value exceeding $600 billion. The company achieved its first revenue from CE-marked Nu.Q® NETs automated product sales in Europe during Q1 2025.
Financial position shows cash and equivalents of $2.6 million as of March 31, 2025, with additional funding of $4.3 million received in Q1 and a subsequent $6.25 million convertible loan note. VolitionRx aims to achieve cash neutrality for full-year 2025.
VolitionRx (NYSE: VNRX), un'azienda multinazionale nel campo dell'epigenetica, ha pubblicato i risultati finanziari del primo trimestre 2025 e aggiornamenti aziendali. La società ha registrato 0,25 milioni di dollari di ricavi, con un aumento del 44% rispetto all'anno precedente, riducendo al contempo il consumo netto di cassa mensile a 1,4 milioni di dollari, una riduzione del 50% rispetto al primo trimestre 2024.
I punti salienti includono discussioni riservate in corso con oltre dieci aziende per la commercializzazione della piattaforma Nu.Q® nella diagnostica umana, con sette potenziali partner il cui valore di mercato combinato supera i 600 miliardi di dollari. La società ha ottenuto i primi ricavi dalla vendita del prodotto automatizzato Nu.Q® NETs con marchio CE in Europa durante il primo trimestre 2025.
La posizione finanziaria mostra 2,6 milioni di dollari in contanti e equivalenti al 31 marzo 2025, con ulteriori finanziamenti di 4,3 milioni di dollari ricevuti nel primo trimestre e un successivo prestito convertibile da 6,25 milioni di dollari. VolitionRx mira a raggiungere la neutralità di cassa per l'intero anno 2025.
VolitionRx (NYSE: VNRX), una empresa multinacional de epigenética, reportó sus resultados financieros del primer trimestre de 2025 y actualizaciones comerciales. La compañía registró 0,25 millones de dólares en ingresos, un aumento del 44% interanual, mientras reducía el gasto neto mensual de efectivo a 1,4 millones de dólares, una reducción del 50% respecto al primer trimestre de 2024.
Los aspectos destacados incluyen discusiones confidenciales en curso con más de diez empresas para la comercialización de la plataforma Nu.Q® en diagnóstico humano, con siete socios potenciales cuyo valor de mercado combinado supera los 600 mil millones de dólares. La empresa logró sus primeros ingresos por ventas del producto automatizado Nu.Q® NETs con marcado CE en Europa durante el primer trimestre de 2025.
La posición financiera muestra 2,6 millones de dólares en efectivo y equivalentes al 31 de marzo de 2025, con financiamiento adicional de 4,3 millones de dólares recibido en el primer trimestre y un posterior préstamo convertible de 6,25 millones de dólares. VolitionRx apunta a alcanzar la neutralidad de efectivo para todo el año 2025.
VolitionRx (NYSE: VNRX)는 다국적 후생유전학 기업으로서 2025년 1분기 재무 결과 및 사업 업데이트를 발표했습니다. 회사는 매출 25만 달러를 기록하며 전년 동기 대비 44% 증가했고, 월간 순 현금 소모는 140만 달러로 2024년 1분기 대비 50% 감소했습니다.
주요 내용으로는 Nu.Q® 플랫폼의 인간 진단 상용화를 위해 10개 이상의 기업과 비밀 협상 중이며, 7개의 잠재 파트너의 시장 가치가 총 6,000억 달러를 초과한다는 점입니다. 회사는 2025년 1분기 유럽에서 CE 인증을 받은 Nu.Q® NETs 자동화 제품 판매로 첫 매출을 달성했습니다.
재무 상태는 2025년 3월 31일 기준 현금 및 현금성 자산 260만 달러를 보유하고 있으며, 1분기에 추가로 430만 달러의 자금을 확보했고 이후 625만 달러의 전환사채를 발행했습니다. VolitionRx는 2025년 전체 기간 동안 현금 중립을 달성하는 것을 목표로 하고 있습니다.
VolitionRx (NYSE : VNRX), une entreprise multinationale en épigénétique, a publié ses résultats financiers du premier trimestre 2025 ainsi que des mises à jour commerciales. La société a enregistré 0,25 million de dollars de revenus, soit une augmentation de 44 % par rapport à l'année précédente, tout en réduisant la consommation nette mensuelle de trésorerie à 1,4 million de dollars, soit une baisse de 50 % par rapport au premier trimestre 2024.
Les points clés incluent des discussions confidentielles en cours avec plus de dix entreprises pour la commercialisation de la plateforme Nu.Q® en diagnostic humain, avec sept partenaires potentiels dont la valeur de marché combinée dépasse 600 milliards de dollars. La société a réalisé ses premiers revenus issus des ventes du produit automatisé Nu.Q® NETs, certifié CE, en Europe au cours du premier trimestre 2025.
La position financière indique 2,6 millions de dollars en liquidités et équivalents au 31 mars 2025, avec un financement supplémentaire de 4,3 millions de dollars reçu au premier trimestre et une note de prêt convertible ultérieure de 6,25 millions de dollars. VolitionRx vise à atteindre la neutralité de trésorerie pour l'ensemble de l'année 2025.
VolitionRx (NYSE: VNRX), ein multinationales Epigenetik-Unternehmen, veröffentlichte seine Finanzergebnisse und Geschäftsupdates für das erste Quartal 2025. Das Unternehmen erzielte Umsätze von 0,25 Millionen US-Dollar, was einem Anstieg von 44 % im Jahresvergleich entspricht, während der monatliche Netto-Cash-Burn auf 1,4 Millionen US-Dollar gesenkt wurde, eine Reduzierung um 50 % gegenüber dem ersten Quartal 2024.
Wichtige Highlights umfassen laufende vertrauliche Gespräche mit über zehn Unternehmen zur Kommerzialisierung der Nu.Q®-Plattform in der Human-Diagnostik, wobei sieben potenzielle Partner einen kombinierten Marktwert von über 600 Milliarden US-Dollar aufweisen. Das Unternehmen erzielte im ersten Quartal 2025 die ersten Umsätze aus dem Verkauf des CE-gekennzeichneten automatisierten Produkts Nu.Q® NETs in Europa.
Die Finanzlage zeigt zum 31. März 2025 Barmittel und Zahlungsmitteläquivalente von 2,6 Millionen US-Dollar, zusätzlich wurden im ersten Quartal 4,3 Millionen US-Dollar an Finanzierung erhalten sowie eine nachfolgende Wandelanleihe über 6,25 Millionen US-Dollar. VolitionRx strebt für das Gesamtjahr 2025 die Cash-Neutralität an.
- Revenue increased 44% year-over-year to $0.25 million in Q1 2025
- First revenue generated from CE-marked Nu.Q® NETs automated product in Europe
- 50% reduction in monthly cash burn compared to Q1 2024
- Secured $4.3 million in funding during Q1, including $1.8 million non-dilutive
- Additional $6.25 million secured through convertible loan note post-quarter
- Cash position decreased to $2.6 million from $3.3 million in December 2024
- Still operating at a significant monthly cash burn of $1.4 million
- Potential dilution risk from convertible loan note repayable in shares
Insights
VolitionRx shows progress commercializing its Nu.Q® platform with first regulated product revenue, but still faces significant cash burn despite 44% revenue growth.
The Q1 2025 results reveal a company at an inflection point. Revenue reached
From a cash perspective, the situation remains challenging but shows improvement. Monthly cash burn averaged
The company's commercial strategy appears to follow a dual approach: pursuing licensing deals with major companies (noting discussions with firms having a combined market value exceeding
Their goal to achieve cash neutrality in 2025 is ambitious given the current burn rate and revenue. With
The convertible loan structure, repayable in cash or shares over 24 months with a 6-month repayment holiday, buys time but creates potential future dilution for shareholders if repaid in equity. This financing approach indicates confidence in near-term commercial progress, but also introduces uncertainty about future share count and ownership structure.
Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m.
Cameron Reynolds, President and Group Chief Executive Officer, said:
"2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the human diagnostics market. I am delighted to report we are in confidential discussions with more than ten companies.
"Notably, the combined market value of seven of these companies exceeds
"Our goal is to secure multiple licensing agreements in the human diagnostics space this year, mirroring our successful strategy in the veterinary market, with diverse deal structures, all with ongoing revenue and some to include milestone payments.
"The second prong of our Nu.Q® NETs commercial strategy is to leverage our granted CE mark, approved in the EU for any NETs related diseases. I am delighted to report that we have reached a significant commercial milestone, in that we recorded our first revenue from sales of our CE-marked Nu.Q® NETs automated product in
Financial Highlights
- Recorded approximately
$0.25million 44% over the first quarter prior year. - Net cash used in operating activities averaged
$1.4 million 50% lower than the first quarter of 2024. - Funding receipts during the first quarter of
$4.3 million $1.8 million - Cash and cash equivalents as of March 31, 2025 totaled approximately
$2.6 million $3.3 million - Subsequent to quarter end finalized a convertible loan note to provide
$6.25 million - Goal to be cash neutral on a Full Year basis in 2025, meaning income, including licensing receipts, matches expenditure on a cash basis.
Event: VolitionRx Limited First Quarter 2025 Earnings and Business Update Conference Call
Date: Friday, May 16, 2025
Time: 8:30 a.m.
Toll/International: 1-201-493-6779
Conference ID: 13753885
Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition and Terig Hughes, Group Chief Financial Officer. The call will provide an update on important events that have taken place in the first quarter of 2025 and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until May 30, 2025. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Investor Relations:
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the exercise of the milestone-linked warrants upon the achievement of such milestone events or otherwise prior to their expiration, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition's cost reduction measures, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-announces-first-quarter-2025-financial-results-and-business-update-302457251.html
SOURCE VolitionRx Limited
FAQ
What was VolitionRx (VNRX) revenue in Q1 2025?
How much cash does VolitionRx (VNRX) have as of March 2025?
What is the status of VolitionRx's Nu.Q® platform commercialization?
How much funding did VolitionRx secure in Q1 2025?
What is VolitionRx's monthly cash burn rate in Q1 2025?
